Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Do You Solve A Problem Like Sequestration?

Executive Summary

FDA and advocates wait for OMB to clarify how the estimated 7.8% budget cut should be implemented, if it is enacted. Former agency officials say it could lead to hiring freezes and program delays.


Related Content

FDA’s Hamburg Details Some Sequestration Impacts On FDA
Hamburg Details Some Sequestration Impact On FDA
FDA Taking “Risk-Based Approach” To Sequestration Cuts
FDA’s 8.2% Solution: Sequestration Would Cut $319 Million
Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows
FDASIA Study Mandates Focus On Performance, But Could Slow Reviews
FDA’s Globalization Strategy Needs To Be More Aggressive, Sen. Brown Suggests
FDA's Projected $20 Mil. In 2013 Biosimilar User Fees Translates Into 68 More Staffers
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts